Barclays Begins Coverage on Humana (HUM)

Share on StockTwits

Barclays began coverage on shares of Humana (NYSE:HUM) in a report released on Thursday morning, Marketbeat.com reports. The firm issued an overweight rating and a $370.00 price target on the insurance provider’s stock.

HUM has been the topic of several other reports. Zacks Investment Research lowered Humana from a buy rating to a hold rating in a research note on Friday, May 18th. ValuEngine lowered Humana from a buy rating to a hold rating in a research note on Saturday, June 2nd. BMO Capital Markets upped their price objective on Humana from $328.00 to $355.00 and gave the company an outperform rating in a research note on Monday, June 25th. Piper Jaffray Companies upped their price objective on Humana from $355.00 to $380.00 and gave the company an overweight rating in a research note on Friday, August 24th. Finally, Bank of America upped their price objective on Humana from $338.00 to $375.00 and gave the company a buy rating in a research note on Thursday, August 2nd. Six equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. The company presently has a consensus rating of Buy and an average price target of $331.11.

HUM stock opened at $337.24 on Thursday. Humana has a 1-year low of $231.90 and a 1-year high of $339.88. The company has a market capitalization of $45.68 billion, a PE ratio of 28.80, a P/E/G ratio of 1.65 and a beta of 0.96. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.43 and a current ratio of 1.43.

Humana (NYSE:HUM) last released its quarterly earnings data on Wednesday, August 1st. The insurance provider reported $3.96 earnings per share for the quarter, beating the consensus estimate of $3.79 by $0.17. Humana had a return on equity of 17.43% and a net margin of 2.48%. The company had revenue of $14.26 billion for the quarter, compared to analyst estimates of $14.16 billion. During the same period in the prior year, the company posted $3.49 EPS. analysts forecast that Humana will post 14.18 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 26th. Investors of record on Friday, September 28th will be given a dividend of $0.50 per share. The ex-dividend date of this dividend is Thursday, September 27th. This represents a $2.00 dividend on an annualized basis and a yield of 0.59%. Humana’s dividend payout ratio (DPR) is presently 17.08%.

In related news, insider Elizabeth D. Bierbower sold 3,092 shares of the stock in a transaction that occurred on Thursday, August 16th. The stock was sold at an average price of $330.00, for a total transaction of $1,020,360.00. Following the sale, the insider now directly owns 14,289 shares in the company, valued at approximately $4,715,370. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Timothy Alan Wheatley sold 11,468 shares of the stock in a transaction that occurred on Tuesday, June 19th. The stock was sold at an average price of $299.40, for a total value of $3,433,519.20. Following the sale, the insider now owns 3,889 shares in the company, valued at $1,164,366.60. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 51,752 shares of company stock worth $16,581,234. 0.60% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Synovus Financial Corp acquired a new position in Humana during the 1st quarter worth $100,000. Sun Life Financial INC lifted its holdings in Humana by 120.7% during the 2nd quarter. Sun Life Financial INC now owns 373 shares of the insurance provider’s stock worth $111,000 after buying an additional 204 shares in the last quarter. Financial Gravity Wealth Inc. acquired a new position in Humana during the 1st quarter worth $113,000. Migdal Insurance & Financial Holdings Ltd. lifted its holdings in Humana by 2,984.6% during the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 401 shares of the insurance provider’s stock worth $119,000 after buying an additional 388 shares in the last quarter. Finally, Stratos Wealth Partners LTD. lifted its holdings in Humana by 448.7% during the 1st quarter. Stratos Wealth Partners LTD. now owns 417 shares of the insurance provider’s stock worth $112,000 after buying an additional 341 shares in the last quarter. Institutional investors and hedge funds own 93.00% of the company’s stock.

About Humana

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company operates through four segments: Retail; Group and Specialty; Healthcare Services; and Individual Commercial. The Retail segment offers Medicare and supplemental benefit plans to individuals or through group accounts.

Read More: Price to Earnings Ratio (PE)

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

29,177 Shares in Unilever N.V.  Purchased by Harrington Investments INC
29,177 Shares in Unilever N.V. Purchased by Harrington Investments INC
Horan Capital Advisors LLC. Invests $186,000 in WesBanco Inc
Horan Capital Advisors LLC. Invests $186,000 in WesBanco Inc
Horan Capital Advisors LLC. Invests $1.05 Million in iShares Short-Term National Muni Bond ETF  Stock
Horan Capital Advisors LLC. Invests $1.05 Million in iShares Short-Term National Muni Bond ETF Stock
Illinois Tool Works Inc.  Stake Increased by Horan Capital Advisors LLC.
Illinois Tool Works Inc. Stake Increased by Horan Capital Advisors LLC.
Horan Capital Advisors LLC. Has $4.37 Million Stake in JPMorgan Ultra-Short Income ETF
Horan Capital Advisors LLC. Has $4.37 Million Stake in JPMorgan Ultra-Short Income ETF
Critical Analysis: Akoustis Technologies  versus ADTRAN
Critical Analysis: Akoustis Technologies versus ADTRAN


Leave a Reply

© 2006-2018 Ticker Report. Google+.